Efforts aimed at translating these concepts into therapeutic approaches to mitigate cardiac hypertrophy and fibrosis face challenges due to the intricate, multifaceted nature of TGF-β signaling (Hanna and Frangogiannis, 2019). This evidence concerns the gene TGFB1 and cardiac hypertrophy.